Considerations for prioritising clinical research using bacteriophage
Open Access
- 17 December 2024
- journal article
- review article
- Published by Portland Press Ltd. in Essays in Biochemistry
- Vol. 68 (5) , 679-686
Abstract
Antimicrobial resistance (AMR) poses a significant global health threat, as it contributes to prolonged illness, higher mortality rates and increased healthcare costs. As traditional antibiotics become less effective, treatments such as bacteriophage therapy offer potential solutions. The question remains, however, on how to set research priorities in the face of a growing number of antibiotic-resistant pathogens, some common and/or dangerous. One standard way of making decisions about which research to prioritise is by using the disability-adjusted life year metric to estimate the current global impact of a disease or condition, combined with considerations of social justice although decisions made at a national level by governments, especially in low income countries with forecasting potential over future needs may look very different. Another approach is based on the needs of researchers and regulators given what we know about the technology itself. The biological characteristics of bacteriophage therapies set challenges to a universal and standardised prioritisation method. A proof of principle is still arguably needed. With a preliminary discussion of the scope and complexity of AMR and AMR therapeutics, we propose some implications of regulatory frameworks aiming to integrate bacteriophage therapy into mainstream medical practice while gathering scientific data on safety and efficacy, enhancing the collective action needed to combat AMR.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council (IAA)
- Biotechnology and Biological Sciences Research Council (HEIF)
This publication has 31 references indexed in Scilit:
- Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational studyNature Microbiology, 2024
- Single-arm phase 3 designs: An oxymoron?Contemporary Clinical Trials, 2024
- The Personalised Randomized Controlled Trial: Evaluation of a new trial designStatistics in Medicine, 2023
- Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic reviewThe Lancet Infectious Diseases, 2022
- Real-World Evidence for Regulatory Decision-Making: Guidance From Around the WorldClinical Therapeutics, 2022
- The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An UpdateDrugs, 2021
- Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteriaClinical Microbiology and Infection, 2021
- Clinical Trials of Bacteriophage Therapeutics2021
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysisThe Lancet Infectious Diseases, 2019
- Registry Contributions to Strengthen Cell and Gene Therapeutic EvidenceMolecular Therapy, 2018